Regenosca provides regenerative medicine technology that enables permanent regrowth of your own native tissues on a self-absorbing mesh, ensuring seamless healing of soft tissue defects and surgical wounds. Our solutions are cost-effective, safe, and designed with surgeons in mind.
TissueSpan is an innovative, natural mesh designed to support seamless soft tissue repair and function as a protective barrier. While not a living tissue, it is engineered to actively attract and organize the patient's own cells upon implantation, initiating the body's natural regenerative processes. Fully absorbable, off-the-shelf, and ready-to-use, TissueSpan ensures easy clinical translation and compatibility with current surgical techniques.
31.07.2024
Regenosca secures CHF 1M Pre-Seed funding to advance endoscopic delivery of innovative TissueSpan bio-implants (venturelab.swiss)
02.10.2023
Venture Leaders Medtech soar high on Boston roadshow (venturelab.swiss)
15.08.2023
Regenosca: The Venture Leaders Medtech developing a technology platform to make implants for soft tissue repair (venturelab.swiss)
14.08.2023
The Venture Leaders Medtech 2023 kick-off meeting sets the course for the Boston roadshow (venturelab.swiss)
24.07.2024
Closing of pre-seed round
15.10.2023
All patients of First-in-Human study operated
01.04.2023
KOL is joining FIrst-in-Human study as investigator
04.10.2022
Closing of convertible loan with private investors
30.08.2022
First patients operated in a First-in-Human study
No Jobs
No videos and documents
Website:
www.regenosca.com
Headquarter:
Lausanne
Foundation Date:
January 2019
Technology:
Sectors: